Ítem
Solo Metadatos

Colombian experience in the treatment of hepatitis c with direct-acting antiviral agents

Mostrar el registro sencillo de la publicación
dc.creatorVarón A.spa
dc.creatorSantos L.spa
dc.creatorTapias M.spa
dc.creatorCáez C.spa
dc.creatorMarín J.I.spa
dc.creatorSantos Ó.spa
dc.creatorGarzón M.spa
dc.creatorBeltrán Ó.spa
dc.creatorGómez-Aldana A.spa
dc.creatorYepes I.J.spa
dc.creatorRondón M.spa
dc.creatorRosselli D.spa
dc.date.accessioned2020-05-25T23:56:58Z
dc.date.available2020-05-25T23:56:58Z
dc.date.created2019spa
dc.description.abstractThere are few published real-world studies on hepatitis C in Latin America. This paper describes a cohort of Colombian subjects treated with direct-acting antiviral agents. A total of 195 patients from 5 hepatology centers in 4 Colombian cities were retrospectively studied. For each patient, serum biomarkers were obtained, and Child-Pugh, MELD, cirrhosis and fibrosis stage were calculated. Additionally, viral load was quantified at initiation, end of treatment and at 12 weeks of completion. Adverse effects were recorded. Patients with liver transplant were compared with non-transplanted patients in terms of serum biomarkers. The patients had received 9 different regimes. The most prevalent viral genotype was 1b (81.5%). Overall, 186 patients (95.4%) attained sustained virologic response. When comparing transplanted vs. non-transplanted patients, those in the non-transplanted group were more likely to have cirrhosis (52.6% vs. 12.5%, p = 0.0004). Pre-treatment viral load was higher in the transplant group (1 743 575 IQR = 1 038 062-4 252 719 vs. 345 769 IQR = 125 806-842 239; p less than 0.0001) as well as ALT and AST levels (82.5 IQR 43.5-115.5 vs. 37.0 IQR = 24.7-73.3; p = 0.0009 and 70 IQR = 41-140 vs. 37 IQR = 24-68; p = 0.004 respectively). Adverse events were reported by 28.7% of the patients; asthenia (5.6%) was the most prevalent. Our results are comparable with those from other countries in terms of therapy and biomarkers. However, our cohort reported less adverse events. Further research is needed in the region. © 2019, Instituto de Investigaciones Medicas. All rights reserved.spa
dc.format.mimetypeapplication/pdf
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/22572
dc.language.isospaspa
dc.publisherInstituto de Investigaciones Medicasspa
dc.relation.citationEndPage36
dc.relation.citationIssueNo. 1
dc.relation.citationStartPage29
dc.relation.citationTitleMedicina (Argentina)
dc.relation.citationVolumeVol. 79
dc.relation.ispartofMedicina (Argentina), Vol.79, No.1 (2019); pp. 29-36spa
dc.relation.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85060579131&partnerID=40&md5=b6aea1ab0494c3cf6d899622796920f3spa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.instnameinstname:Universidad del Rosariospa
dc.source.reponamereponame:Repositorio Institucional EdocURspa
dc.subject.keywordAlanine aminotransferasespa
dc.subject.keywordviraleng
dc.subject.keywordAspartate aminotransferasespa
dc.subject.keywordAsunaprevirspa
dc.subject.keywordBiological markerspa
dc.subject.keywordDaclatasvirspa
dc.subject.keywordDaclatasvir plus ribavirinspa
dc.subject.keywordDaclatasvir plus simeprevirspa
dc.subject.keywordDasabuvirspa
dc.subject.keywordLedipasvirspa
dc.subject.keywordLedipasvir plus ribavirinspa
dc.subject.keywordLedipasvir plus sofosbuvirspa
dc.subject.keywordOmbitasvirspa
dc.subject.keywordParitaprevirspa
dc.subject.keywordParitaprevir plus ribavirinspa
dc.subject.keywordRibavirinspa
dc.subject.keywordRibavirin plus sofosbuvirspa
dc.subject.keywordRitonavirspa
dc.subject.keywordSimeprevirspa
dc.subject.keywordSofosbuvirspa
dc.subject.keywordUnclassified drugspa
dc.subject.keywordAntivirus agentspa
dc.subject.keywordVirus rnaspa
dc.subject.keywordAdultspa
dc.subject.keywordAgedspa
dc.subject.keywordAlanine aminotransferase blood levelspa
dc.subject.keywordAnemiaspa
dc.subject.keywordAnxiety disorderspa
dc.subject.keywordArticlespa
dc.subject.keywordAspartate aminotransferase blood levelspa
dc.subject.keywordAstheniaspa
dc.subject.keywordBrain diseasespa
dc.subject.keywordCholelithiasisspa
dc.subject.keywordCohort analysisspa
dc.subject.keywordColombiaspa
dc.subject.keywordDiarrheaspa
dc.subject.keywordDrug efficacyspa
dc.subject.keywordFatiguespa
dc.subject.keywordFemalespa
dc.subject.keywordGenotypespa
dc.subject.keywordHeadachespa
dc.subject.keywordHepatitis cspa
dc.subject.keywordHumanspa
dc.subject.keywordIntermethod comparisonspa
dc.subject.keywordLiver cirrhosisspa
dc.subject.keywordLiver toxicityspa
dc.subject.keywordLiver transplantationspa
dc.subject.keywordMajor clinical studyspa
dc.subject.keywordMalespa
dc.subject.keywordMulticenter studyspa
dc.subject.keywordNauseaspa
dc.subject.keywordNonhumanspa
dc.subject.keywordPruritusspa
dc.subject.keywordRashspa
dc.subject.keywordRetrospective studyspa
dc.subject.keywordSustained virologic responsespa
dc.subject.keywordTreatment outcomespa
dc.subject.keywordVirus loadspa
dc.subject.keywordVomitingspa
dc.subject.keywordClinical trialspa
dc.subject.keywordCombination drug therapyspa
dc.subject.keywordGeneticsspa
dc.subject.keywordHepacivirusspa
dc.subject.keywordHepatitis cspa
dc.subject.keywordMiddle agedspa
dc.subject.keywordNonparametric testspa
dc.subject.keywordAgedspa
dc.subject.keywordAntiviral agentsspa
dc.subject.keywordColombiaspa
dc.subject.keywordDrug therapyeng
dc.subject.keywordFemalespa
dc.subject.keywordGenotypespa
dc.subject.keywordHepacivirusspa
dc.subject.keywordHepatitis cspa
dc.subject.keywordHumansspa
dc.subject.keywordLiver transplantationspa
dc.subject.keywordMalespa
dc.subject.keywordMiddle agedspa
dc.subject.keywordRetrospective studiesspa
dc.subject.keywordRnaeng
dc.subject.keywordStatisticseng
dc.subject.keywordSustained virologic responsespa
dc.subject.keywordViral loadspa
dc.subject.keywordAntiviral agentsspa
dc.subject.keywordChronic hepatitisspa
dc.subject.keywordDrug therapyspa
dc.subject.keywordHepatitis cspa
dc.subject.keywordLiver transplantationspa
dc.subject.keywordTreatment outcomespa
dc.titleColombian experience in the treatment of hepatitis c with direct-acting antiviral agentsspa
dc.title.TranslatedTitleExperiencia Colombiana en el tratamiento de la hepatitis c con agentes antivirales de acción directaspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Colecciones
Artículos